Angeles Shunashy Galindo-Feria
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Angeles Shunashy Galindo-Feria has a total of 213 co-authors. Here are the top co-authors by number of shared publications:
- Ingrid E. Lundberg
Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet Stockholm Sweden
13 shared publications Maryam Dastmalchi
Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, and Center for Molecular Medicine Karolinska University Hospital Stockholm Sweden
10 shared publications- Begum Horuluoglu
Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden
6 shared publications - Antonella Notarnicola
Division of Rheumatology, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
4 shared publications Lara Dani
Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, and Center for Molecular Medicine Karolinska University Hospital Stockholm Sweden
4 shared publicationsBegum Horuluoglu
Department of Medicine, Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden
3 shared publications
Latest Publications
- 1 October 2026
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 38 (6) , 456-469
Myositis autoantibodies: from new specificities to new paradigms
Purpose of review: Myositis-specific autoantibodies have long been used to classify patients into clinically meaningful subsets; however, recent studies show that the field is moving beyond the simple question of which autoantibody is present. This review examines how emerging specificities, epitope architecture, autoantibody coexistence, pathogenic mechanisms, and detection platforms are reshaping the interpretation of myositis serology. Recent findings: Recent work has expanded the autoantibody repertoire through the identification of additional autoantibody specificities, multiprotein antigenic complexes, and transcriptional regulators. At the same time, epitope-level studies reveal that patients sharing the same autoantibody specificity may recognize different antigenic regions, with potential implications for phenotype, prognosis, and assay interpretation. Evidence also challenges the view of myositis autoantibodies as passive biomarkers: selected specificities may mediate complement-dependent muscle injury, amplify inflammatory circuits, or interfere with intracellular antigen function. Meanwhile, new detection platforms have not only improved discovery but also exposed limitations related to conformational epitopes, cross-reactivity, false seronegativity, and assay standardization. Summary: Novelty in myositis autoantibodies should be understood not only as new targets but also as new paradigms linking antigen structure, immune mechanisms, detection methods, and clinical actionability.
- 1 October 2026
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 38 (6) , 456-469
Myositis autoantibodies: from new specificities to new paradigms
Purpose of review: Myositis-specific autoantibodies have long been used to classify patients into clinically meaningful subsets; however, recent studies show that the field is moving beyond the simple question of which autoantibody is present. This review examines how emerging specificities, epitope architecture, autoantibody coexistence, pathogenic mechanisms, and detection platforms are reshaping the interpretation of myositis serology. Recent findings: Recent work has expanded the autoantibody repertoire through the identification of additional autoantibody specificities, multiprotein antigenic complexes, and transcriptional regulators. At the same time, epitope-level studies reveal that patients sharing the same autoantibody specificity may recognize different antigenic regions, with potential implications for phenotype, prognosis, and assay interpretation. Evidence also challenges the view of myositis autoantibodies as passive biomarkers: selected specificities may mediate complement-dependent muscle injury, amplify inflammatory circuits, or interfere with intracellular antigen function. Meanwhile, new detection platforms have not only improved discovery but also exposed limitations related to conformational epitopes, cross-reactivity, false seronegativity, and assay standardization. Summary: Novelty in myositis autoantibodies should be understood not only as new targets but also as new paradigms linking antigen structure, immune mechanisms, detection methods, and clinical actionability.
- Open Access
- 19 September 2026
- Published by Elsevier in SSRN Electronic Journal
Hybrid Compartment-Based Segmentation Enables Xenium Spatial Transcriptomics in Inflamed Human Skeletal Muscle Biopsies
Inflamed skeletal muscle is challenging for imaging-based spatial transcriptomics because large multinucleated myofibers are poorly represented by nucleus-centred segmentation. We developed a compartment-first Xenium workflow in biopsies from 11 patients with inflammatory muscle disease. StarDist first detected nucleated objects, which were consolidated and subtracted from the tissue region. Cellpose then segmented the residual sarcolemmal myofiber compartment, after which individual nucleated objects were restored, and all geometries were imported into Xenium Ranger for transcript reassignment. Across all samples, the median transcripts per segmented object increased from 33 with the default Xenium segmentation to 68 after custom reassignment and to 75 after quality-control filtering. The workflow improved anatomical representation of myofibers, preserved nucleated interstitial compartments, and supported clustering of expected muscle, immune, vascular, and stromal populations. Open-source scripts provide a reproducible framework for Xenium analysis of inflamed skeletal muscle.
- 19 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessHybrid Compartment-Based Segmentation Enables Xenium Spatial Transcriptomics in Inflamed Human Skeletal Muscle Biopsies
Inflamed skeletal muscle is challenging for imaging-based spatial transcriptomics because large multinucleated myofibers are poorly represented by nucleus-centred segmentation. We developed a compartment-first Xenium workflow in biopsies from 11 patients with inflammatory muscle disease. StarDist first detected nucleated objects, which were consolidated and subtracted from the tissue region. Cellpose then segmented the residual sarcolemmal myofiber compartment, after which individual nucleated objects were restored, and all geometries were imported into Xenium Ranger for transcript reassignment. Across all samples, the median transcripts per segmented object increased from 33 with the default Xenium segmentation to 68 after custom reassignment and to 75 after quality-control filtering. The workflow improved anatomical representation of myofibers, preserved nucleated interstitial compartments, and supported clustering of expected muscle, immune, vascular, and stromal populations. Open-source scripts provide a reproducible framework for Xenium analysis of inflamed skeletal muscle.
- Open Access
- 27 August 2026
- Published by Wiley in Arthritis & Rheumatology
Plasma proteome reflects tissue damage and clinical manifestations in patients with inflammatory myopathies
Objective: Tissue‐specific biomarkers that are reliable and associated with clinical manifestations of idiopathic inflammatory myopathy (IIM) are lacking. The blood circulation in individuals serves as a central conduit, allowing communication between tissues and facilitating clearance and recycling of tissue‐derived proteins. Thus, we applied a dual antibody‐based proximity extension assay to profile >1000 proteins in subtypes of patients with IIM. Methods: Plasma samples from 201 patients diagnosed with IIM at Karolinska University Hospital were analyzed using Olink Proximity Extension Assay technology. Clinical manifestations, disease activity measurements, and laboratory results were collected. First, we evaluated differential protein abundance across IIM subtypes. Then we calculated tissue scores for each disease subtype using tissue gene expression databases. Finally, interferon (IFN) pathway scores were calculated. Results: Plasma from patients with dermatomyositis was enriched for IFN signalling and skin associated proteins, anti‐synthetase syndrome (ASyS) for lung associated proteins, immune‐mediated necrotizing myopathy (IMNM) for muscle associated proteins, and inclusion body myositis for T cell response proteins. Patients with IMNM showed the highest tissue score for skeletal muscles, and ASyS for lung tissue score. Skeletal muscle scores correlated strongly with muscle disease activity visual analog scale scores, creatine kinase levels, and muscle weakness score. Patients with interstitial lung disease along with anti‐MDA5 and those with anti‐Jo1 autoantibodies showed differential enrichment of surfactant proteins and IFN pathway activation. Conclusions: Circulatory proteome is a promising tool to capture distinct tissue‐specific responses that correlate with disease activity and tissue injury in patients with IIM. image
- 27 August 2026
- Published by Wiley in Arthritis & Rheumatology
Open AccessPlasma proteome reflects tissue damage and clinical manifestations in patients with inflammatory myopathies
Objective: Tissue‐specific biomarkers that are reliable and associated with clinical manifestations of idiopathic inflammatory myopathy (IIM) are lacking. The blood circulation in individuals serves as a central conduit, allowing communication between tissues and facilitating clearance and recycling of tissue‐derived proteins. Thus, we applied a dual antibody‐based proximity extension assay to profile >1000 proteins in subtypes of patients with IIM. Methods: Plasma samples from 201 patients diagnosed with IIM at Karolinska University Hospital were analyzed using Olink Proximity Extension Assay technology. Clinical manifestations, disease activity measurements, and laboratory results were collected. First, we evaluated differential protein abundance across IIM subtypes. Then we calculated tissue scores for each disease subtype using tissue gene expression databases. Finally, interferon (IFN) pathway scores were calculated. Results: Plasma from patients with dermatomyositis was enriched for IFN signalling and skin associated proteins, anti‐synthetase syndrome (ASyS) for lung associated proteins, immune‐mediated necrotizing myopathy (IMNM) for muscle associated proteins, and inclusion body myositis for T cell response proteins. Patients with IMNM showed the highest tissue score for skeletal muscles, and ASyS for lung tissue score. Skeletal muscle scores correlated strongly with muscle disease activity visual analog scale scores, creatine kinase levels, and muscle weakness score. Patients with interstitial lung disease along with anti‐MDA5 and those with anti‐Jo1 autoantibodies showed differential enrichment of surfactant proteins and IFN pathway activation. Conclusions: Circulatory proteome is a promising tool to capture distinct tissue‐specific responses that correlate with disease activity and tissue injury in patients with IIM. image
- Open Access
Plasma proteome reflects tissue damage and clinical manifestations in patients with inflammatory myopathies
Objective: Tissue-specific biomarkers that are reliable and associated with clinical manifestations of idiopathic inflammatory myopathy (IIM) are lacking. The blood circulation in individuals serves as a central conduit, allowing communication between tissues and facilitating clearance and recycling of tissue-derived proteins. Thus we applied a dual antibody-based proximity extension assay to profile the plasma proteome in subtypes of patients with IIM. Methods: Plasma samples from 201 patients diagnosed with IIM at Karolinska University Hospital were analyzed using Olink. Clinical manifestations, disease activity measurements, and laboratory results were collected. First, we evaluated differential protein abundance across IIM subtypes. Then we calculated tissue scores for each disease subtype using tissue gene expression databases. Finally, interferon (IFN) and complement pathway scores were calculated. Results: Plasma from patients with dermatomyositis was enriched for IFN signaling and skin associated proteins, anti-synthetase syndrome (ASyS) for lung associated proteins, immune-mediated necrotizing myopathy (IMNM) for muscle associated proteins, and inclusion body myositis for T cell response proteins. Patients with IMNM showed the highest tissue score for skeletal muscles, and ASyS for lung tissue score. Skeletal muscle scores correlated strongly with muscle disease activity visual analog scale scores, creatinine kinase levels, and muscle weakness score. Patients with interstitial lung disease along with and those with anti-Jo1 autoantibodies showed differential enrichment of surfactant proteins and IFN pathway activation. Conclusions: Circulatory proteome is a promising tool to capture distinct tissue-specific responses that correlate with disease activity and tissue injury in patients with IIM.
Open AccessPlasma proteome reflects tissue damage and clinical manifestations in patients with inflammatory myopathies
Objective: Tissue-specific biomarkers that are reliable and associated with clinical manifestations of idiopathic inflammatory myopathy (IIM) are lacking. The blood circulation in individuals serves as a central conduit, allowing communication between tissues and facilitating clearance and recycling of tissue-derived proteins. Thus we applied a dual antibody-based proximity extension assay to profile the plasma proteome in subtypes of patients with IIM. Methods: Plasma samples from 201 patients diagnosed with IIM at Karolinska University Hospital were analyzed using Olink. Clinical manifestations, disease activity measurements, and laboratory results were collected. First, we evaluated differential protein abundance across IIM subtypes. Then we calculated tissue scores for each disease subtype using tissue gene expression databases. Finally, interferon (IFN) and complement pathway scores were calculated. Results: Plasma from patients with dermatomyositis was enriched for IFN signaling and skin associated proteins, anti-synthetase syndrome (ASyS) for lung associated proteins, immune-mediated necrotizing myopathy (IMNM) for muscle associated proteins, and inclusion body myositis for T cell response proteins. Patients with IMNM showed the highest tissue score for skeletal muscles, and ASyS for lung tissue score. Skeletal muscle scores correlated strongly with muscle disease activity visual analog scale scores, creatinine kinase levels, and muscle weakness score. Patients with interstitial lung disease along with and those with anti-Jo1 autoantibodies showed differential enrichment of surfactant proteins and IFN pathway activation. Conclusions: Circulatory proteome is a promising tool to capture distinct tissue-specific responses that correlate with disease activity and tissue injury in patients with IIM.
- Top Cited PapersOpen Access
- 9 January 2026
- Published by Elsevier in Journal of Autoimmunity
- Vol. 158, 103522
Sera from patients with dermatomyositis and antisynthetase syndrome mediate muscle weakness, impair mitochondrial respiration and induce local cytokine production in muscle tissue
- 9 January 2026
- Published by Elsevier in Journal of Autoimmunity
- Vol. 158, 103522
Top Cited PapersOpen AccessSera from patients with dermatomyositis and antisynthetase syndrome mediate muscle weakness, impair mitochondrial respiration and induce local cytokine production in muscle tissue
- Open Access
- 25 October 2025
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (2) , 360-369
Autoreactive T cells identified in patients with anti-Jo1+ antisynthetase syndrome recognise a new epitope on histidyl t-RNA synthetase
- 25 October 2025
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (2) , 360-369
Open AccessAutoreactive T cells identified in patients with anti-Jo1+ antisynthetase syndrome recognise a new epitope on histidyl t-RNA synthetase
- 28 August 2024
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 83 (12) , 1796-1797
Serum from patients with idiopathic inflammatory myopathy induces skeletal muscle weakness
- 28 August 2024
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 83 (12) , 1796-1797
Serum from patients with idiopathic inflammatory myopathy induces skeletal muscle weakness
- Open Access
- 4 June 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (3) , 1482-1492
Anti-FHL1 autoantibodies in adult patients with myositis: a longitudinal follow-up analysis
To determine prevalence and clinical associations of anti-FHL1 autoantibodies in patients with idiopathic inflammatory myopathies (IIM), and to evaluate autoantibody levels over time. Sera at the time of diagnosis from patients with IIM (n = 449), autoimmune disease controls (DC, n = 130), neuromuscular diseases (NMD, n = 16) and healthy controls (HC, n = 100) were analyzed for anti-FHL1 autoantibodies by Enzyme-Linked ImmunoSorbent Assay (ELISA). Patients with IIM FHL1+ and FHL1- were included in a longitudinal analysis. Serum levels were correlated to disease activity. Autoantibodies to FHL1 were more frequent in patients with IIM (122/449, 27%) compared with DC (Autoimmune DC and NMD, 13/146, 9%, p< 0.001) and HC (3/100,3%, p< 0.001). Anti-FHL1 levels were higher in IIM [median (IQR)=0.62 (0.15–1.04)] in comparison with DC [0.22 (0.08–0.58)], HC [0.35 (0.23–0.47)] and NMD [0.48 (0.36–0.80)] p< 0.001. Anti-FHL1+ patients with IIM were younger at time of diagnosis compared with the anti-FHL1- group (p= 0.05) and were seronegative for other autoantibodies in 25%. In the first follow-up anti-FHL1+ sample 20/33 (60%) positive at baseline had turned negative for anti-FHL1 autoantibodies. Anti-FHL1 autoantibodies rarely appeared after initiating treatment. Anti-FHL1 autoantibody levels correlated with CK (r = 0.62, p= 0.01), disease activity measure MYOACT (n = 14, p= 0.004) and inversely with manual muscle test-8 (r=-0.59, p= 0.02) at baseline. Anti-FHL1 autoantibodies were present in 27% of patients with IIM, of these 25% were negative for other autoantibodies. Other autoimmune diseases had lower frequencies and levels. Anti-FHL1 levels often decreased with immunosuppressive treatment, correlated with disease activity measures at diagnosis and rarely appeared after start of treatment.
- 4 June 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (3) , 1482-1492
Open AccessAnti-FHL1 autoantibodies in adult patients with myositis: a longitudinal follow-up analysis
To determine prevalence and clinical associations of anti-FHL1 autoantibodies in patients with idiopathic inflammatory myopathies (IIM), and to evaluate autoantibody levels over time. Sera at the time of diagnosis from patients with IIM (n = 449), autoimmune disease controls (DC, n = 130), neuromuscular diseases (NMD, n = 16) and healthy controls (HC, n = 100) were analyzed for anti-FHL1 autoantibodies by Enzyme-Linked ImmunoSorbent Assay (ELISA). Patients with IIM FHL1+ and FHL1- were included in a longitudinal analysis. Serum levels were correlated to disease activity. Autoantibodies to FHL1 were more frequent in patients with IIM (122/449, 27%) compared with DC (Autoimmune DC and NMD, 13/146, 9%, p< 0.001) and HC (3/100,3%, p< 0.001). Anti-FHL1 levels were higher in IIM [median (IQR)=0.62 (0.15–1.04)] in comparison with DC [0.22 (0.08–0.58)], HC [0.35 (0.23–0.47)] and NMD [0.48 (0.36–0.80)] p< 0.001. Anti-FHL1+ patients with IIM were younger at time of diagnosis compared with the anti-FHL1- group (p= 0.05) and were seronegative for other autoantibodies in 25%. In the first follow-up anti-FHL1+ sample 20/33 (60%) positive at baseline had turned negative for anti-FHL1 autoantibodies. Anti-FHL1 autoantibodies rarely appeared after initiating treatment. Anti-FHL1 autoantibody levels correlated with CK (r = 0.62, p= 0.01), disease activity measure MYOACT (n = 14, p= 0.004) and inversely with manual muscle test-8 (r=-0.59, p= 0.02) at baseline. Anti-FHL1 autoantibodies were present in 27% of patients with IIM, of these 25% were negative for other autoantibodies. Other autoimmune diseases had lower frequencies and levels. Anti-FHL1 levels often decreased with immunosuppressive treatment, correlated with disease activity measures at diagnosis and rarely appeared after start of treatment.
- Open Access
Serum from patients with Idiopathic inflammatory myopathy induces skeletal muscle weakness
Idiopathic inflammatory myopathies (IIM) are a group of systemic autoimmune inflammatory disorders that primarily affect striated muscles leading to weakness and accelerated fatigue. The disseminated muscle phenotype points to systemic humoral factors as mediators of the disease. Autoantibodies are important biomarkers for disease classification; it is not known if they play a direct role in IIM disease development. This study aims to investigate if IIM patient serum or isolated IgG could directly impair contractile function in muscle. Isolated flexor digitorum brevis (FDB) muscles from healthy mice were exposed to serum (10-50%) from healthy controls or patients with recent onset IIM. Some muscles were exposed to isolated total IgG (50 or 150μg/ml) from patients with IIM. Muscle force in whole muscles was measured before and after exposure to sera or IgG. Muscle force and intracellular [Ca 2+ ] in single muscle fibers were measured after exposure to serum. FDB muscles exposed to serum from patients with IIM displayed a marked reduction in force production in both 10% and 50% serum. Moreover, single myofibers dissected from FDB muscles exposed to IIM sera displayed lower force but unaffected Ca 2+ release during contractions, which indicates myofibrillar dysfunction, but not intracellular Ca 2+ release, as the cause to weakness. FDB muscles exposed to total IgG from IIM patients did not display any reduction in muscle force. In conclusion IIM patient serum, but not total IgG, impairs force production in skeletal muscle fibers. As the experiments were performed in isolated muscle, our results cannot be explained by infiltrating immune cells, impaired neuronal or vascular functions. This suggests that humoral factors play a direct role in the pathogenesis of muscle weakness in recent onset IIM.
Open AccessSerum from patients with Idiopathic inflammatory myopathy induces skeletal muscle weakness
Idiopathic inflammatory myopathies (IIM) are a group of systemic autoimmune inflammatory disorders that primarily affect striated muscles leading to weakness and accelerated fatigue. The disseminated muscle phenotype points to systemic humoral factors as mediators of the disease. Autoantibodies are important biomarkers for disease classification; it is not known if they play a direct role in IIM disease development. This study aims to investigate if IIM patient serum or isolated IgG could directly impair contractile function in muscle. Isolated flexor digitorum brevis (FDB) muscles from healthy mice were exposed to serum (10-50%) from healthy controls or patients with recent onset IIM. Some muscles were exposed to isolated total IgG (50 or 150μg/ml) from patients with IIM. Muscle force in whole muscles was measured before and after exposure to sera or IgG. Muscle force and intracellular [Ca 2+ ] in single muscle fibers were measured after exposure to serum. FDB muscles exposed to serum from patients with IIM displayed a marked reduction in force production in both 10% and 50% serum. Moreover, single myofibers dissected from FDB muscles exposed to IIM sera displayed lower force but unaffected Ca 2+ release during contractions, which indicates myofibrillar dysfunction, but not intracellular Ca 2+ release, as the cause to weakness. FDB muscles exposed to total IgG from IIM patients did not display any reduction in muscle force. In conclusion IIM patient serum, but not total IgG, impairs force production in skeletal muscle fibers. As the experiments were performed in isolated muscle, our results cannot be explained by infiltrating immune cells, impaired neuronal or vascular functions. This suggests that humoral factors play a direct role in the pathogenesis of muscle weakness in recent onset IIM.
- Open Access
- 26 September 2023
- Published by Elsevier in EBioMedicine
- Vol. 96, 104804
Distinct HLA associations with autoantibody-defined subgroups in idiopathic inflammatory myopathies
- 26 September 2023
- Published by Elsevier in EBioMedicine
- Vol. 96, 104804
Open AccessDistinct HLA associations with autoantibody-defined subgroups in idiopathic inflammatory myopathies